GIST

• GIST
• Clinical correlation between different C-kit exon mutations and clinical outcome Imatinib mesylate treatment in Gist patients
• GIST
• Gastroenteropancreatic neuroendocrine tumors
• Clinicopathological features of wild-type GISTs based on multiple-gene panel analysis
• Synchronous adenocarcinoma and gastrointestinal stromal tumors in the stomach
• Extra-Gastrointestinal stromal tumor and tumor lysis syndrome, A case-report
• Reduced and re-escalated dose of sunitinib was adequately effective against gastrointestinal stromal tumor of the small intestine: a case report
• Retrospective Analysis of Outcome in GIST patients on Imatinib in Sarawak General Hospital: A Single Institution Experience
• Primary GIST Recurrence Halted During 5-Year Imatinib Therapy
• VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresec...
• Quantitative Multiplexed Immune Profiling of Advanced Gastrointestinal Stromal Tumors (GISTs): Impact of tyrosine kinase inhibitors on immune envir...
• Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST.
• Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced...
• Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study
• Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib
• Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventiona...
• Correlation of ctDNA and response in patients (pts) with PDGFR_ D842 GIST treated with avapritinib
• Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma
• State of Art: Recommendation for adjuvant treatment in GIST
• Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRa Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIS...
• ESMO 2018 Congress
• PDGFRA in Gastrointestinal Stromal Tumours (GIST): ESMO Biomarker Factsheet
• KIT and PDGFRA Wild-type Gastrointestinal Stromal Tumours (GISTs): ESMO Biomarker Factsheet
• KIT in Gastrointestinal Stromal Tumours (GIST): ESMO Biomarker Factsheet

• « Previous
• 1
• 2
• ...
• 6
• Next »